Condition
Recurrent Low-Grade Glioma
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Mirdametinib
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Mirdametinib1
Active Sponsors
- St. Jude Children's Research Hospital1
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1
Top Investigators
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Related Conditions
- Progressive Lowgrade Glioma1
- Lowgrade Glioma1